Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 4, 2011, Pages 372-377

  Krane, L Spencer ^a   Menon, Mani ^a   Kaul, Sanjeev A ^a   Siddiqui, Sameer A ^a   Wambi, Christel ^a   Peabody, James O ^a   Agarwal, Piyush K ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Biopsy; Gleason score; Pathologic upgrading; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BIOCHEMICAL COMPOSITION; BIOCHEMICAL RECURRENCE; CANCER DIAGNOSIS; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECTUM BIOPSY; RECURRENT DISEASE; TRANSRECTAL ULTRASONOGRAPHY;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 79959861910     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.04.018     Document Type: Article

References (21)

1. Dong F., Jones J.S., Stephenson A.J., et al. Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol 2008, 179:896-900. Discussion.
2. Gofrit O.N., Zorn K.C., Taxy J.B., et al. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer. J Urol 2007, 178:1925-1928.
3. Kulkarni G.S., Lockwood G., Evans A., et al. Clinical predictors of Gleason score upgrading: Implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 2007, 109:2432-2438.
4. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125-135.
5. Palma D., Tyldesley S., Pickles T. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy. Cancer 2008, 112:1941-1948.
6. Berger A.P., Deibl M., Strasak A., et al. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: Results from a screening population. Urology 2006, 68:1067-1071.
7. Loeb S., Sutherland D.E., D'Amico A.V., et al. PSA velocity is associated with Gleason score in radical prostatectomy specimen: Marker for prostate cancer aggressiveness. Urology 2009, 72:1116-1120. Discussion 20.
8. Pinsky P.F., Andriole G., Crawford E.D., et al. Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 2007, 109:1689-1695.
9. Choo R., Klotz L., Danjoux C., et al. Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002, 167:1664-1669.
10. Dall'Era M.A., Konety B.R., Cowan J.E., et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008, 112:2664-2670.
11. King C.R., Freedland S.J., Terris M.K., et al. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: A report from SEARCH. Urology 2007, 69:732-737.
12. Cookson M.S., Aus G., Burnett A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007, 177:540-545.
13. Pinthus J.H., Witkos M., Fleshner N.E., et al. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: Implication on outcome. J Urol 2006, 176:979-984. Discussion 84.
14. Gleason D.F. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992, 23:273-279.
15. Freedland S.J., Dorey F., Aronson W.J. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 2001, 57:476-480.
16. Thiel R., Pearson J.D., Epstein J.I., et al. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer. Urology 1997, 49:716-720.
17. Patel D.A., Presti J.C., McNeal J.E., et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005, 23:6157-6162.
18. van den Bergh R.C., Roemeling S., Roobol M.J., et al. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer-a review. Eur Urol 2008, 54:505-516.
19. Vickers A.J., Savage C., O'Brien M.F., et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009, 27:398-403.
20. Cooperberg M.R., Lubeck D.P., Meng M.V., et al. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 2004, 22:2141-2149.
21. Desireddi N.V., Roehl K.A., Loeb S., et al. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007, 70:950-955.